Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436160 · ClinicalTrials.gov registry record · Early Phase 1
Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds
A Early Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT03436160 is a Early Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 18 participants.
The verdict
NCT03436160, a Early Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Open-label, randomized, microdose study
Interventions
- DRUG WR826647
- DRUG WR909388
- DRUG WR909390
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2018-11-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03436160
The ClinicalTrials.gov registry entry for NCT03436160 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which WR826647 is the first listed.
NCT03436160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03436160 about?
NCT03436160 is a clinical study titled "Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds". Open-label, randomized, microdose study
What is the current status of trial NCT03436160?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2018-08-10. Estimated completion is 2018-11-03.
What interventions are being tested in trial NCT03436160?
The interventions under investigation include: WR826647 (DRUG), WR909388 (DRUG), WR909390 (DRUG).
Who is sponsoring clinical trial NCT03436160?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.